Cortexyme
-
Four biotech companies announce pricings of IPOs, looking to raise more than $300M
NextCure, Milestone Pharmaceuticals, Cortexyme and Axcella Health all said Wednesday that they would begin trading on the Nasdaq Thursday.
-
Firm targeting potential bacterial role in Alzheimer’s gets $76 million Series B
Cortexyme has also finished enrolling healthy volunteers in the Phase I study of lead candidate COR388.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.